What it means for seniors, research, stocks

President Donald Trump is expected to sign an executive order that would significantly expand access to cannabis, with far-reaching implications for both consumers and the healthcare industry. The proposed order would reclassify cannabis as a Schedule III drug, placing it alongside Tylenol with codeine, rather than its current classification as a Schedule I drug, which is in the same category as heroin and LSD.

Background and Context

The reclassification of cannabis has been a topic of discussion for some time, with many advocates arguing that it is a necessary step to allow for more research and access to the drug for medical purposes. The proposed order would also authorize a pilot program allowing Medicare to cover cannabis products for seniors, specifically those containing cannabidiol (CBD), which is used to treat chronic pain, sleep deprivation, and other age-related ailments.

CBD has gained popularity in recent years, with many companies incorporating it into their products, from canned cocktails to body lotions. However, despite its growing popularity, CBD has yet to receive full backing from federal drug regulators. The FDA has only approved one CBD-based drug, Epidiolex, which is used to treat rare forms of epilepsy.

Implications and Controversies

The proposed order has sparked controversy, with some experts arguing that it could endanger seniors, who often take multiple medications, and that there is limited clinical evidence to support the use of cannabis-derived products for medical purposes. Others argue that the reclassification of cannabis could lead to more research and a better understanding of its potential benefits and risks.

Some critics also argue that the Medicare provision is not based on science, but rather on financial interests. Meg Haney, director of the Cannabis Research Laboratory at Columbia University, stated that “it’s not at all based on science. This is all based on money, and it’s egregious. That’s not the way we make medical decisions.”

Investing and Business Implications

The reclassification of cannabis could have significant implications for the cannabis industry, with some experts predicting that it could lead to an influx of institutional investments and a shift in the way cannabis companies operate. Timothy Seymour, founder and chief investment officer of Seymour Asset Management, stated that “the valuation of the sector will be worth a lot more because institutional investors will be allowed in, will have access and will have liquidity, and exchanges will trade them.”

However, the reclassification of cannabis could also spell trouble for smaller cannabis businesses, as larger pharmaceutical companies may be better equipped to navigate the regulatory landscape and fund the necessary research and clinical trials. Ben Kovler, CEO of Green Thumb Industries, foresees more competition among pharmaceutical companies and cannabis companies to achieve medical breakthroughs.

Conclusion

The proposed executive order to reclassify cannabis as a Schedule III drug has significant implications for both consumers and the healthcare industry. While some experts argue that it could lead to more research and access to cannabis for medical purposes, others argue that it could endanger seniors and is not based on science. As the cannabis industry continues to evolve, it is likely that we will see more investment, research, and innovation in the sector, but it is crucial to approach this development with caution and careful consideration of the potential risks and benefits.